{"id":"cggv:34354e8f-4343-4fba-82ba-e49579e504bbv1.0","type":"EvidenceStrengthAssertion","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"cggv:34354e8f-4343-4fba-82ba-e49579e504bb_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10006","date":"2019-02-06T17:00:00.000Z","role":"Approver"},{"id":"cggv:34354e8f-4343-4fba-82ba-e49579e504bb_publish_contrib","agent":"http://dataexchange.clinicalgenome.org/agent/10006","date":"2020-09-01T00:00:00Z","role":"Publisher"}],"evidence":[{"id":"cggv:34354e8f-4343-4fba-82ba-e49579e504bb_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:34354e8f-4343-4fba-82ba-e49579e504bb_ad_null_el","type":"EvidenceLine","evidence":[{"id":"cggv:d699f9e1-1b32-4e91-9451-b8b44fabcee2_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"cggv:bead1233-d615-43a1-bd95-6b44c528af4b","type":"Proband","ageType":"AgeAtReport","ageUnit":"Months","ageValue":22,"detectionMethod":"The genotyping method for this patient was not specified, however the authors note that subjects were assayed on a variety of platforms that include array-CGH, BeadChip SNP arrays, Whole genome SNP array, and oligo arrays.","phenotypeFreeText":"Began walking at 22 months old. Seizures began at 18 months with myoclonic and atonic presentations. thinning of cortical white matter was observed in the patient by T2 axial brain imaging (Figure 3D). EEG readings from the patient show multifocal epileptiform and poorly developed anterior-posterior gradient (figure 4B)","phenotypes":["obo:HP_0012171","obo:HP_0011170","obo:HP_0001288","obo:HP_0010841","obo:HP_0002500","obo:HP_0001270"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:d699f9e1-1b32-4e91-9451-b8b44fabcee2_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:6fd8f1d4-baa0-49ac-a99d-777563a9c68a","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.88729319del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913184800"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23389741","type":"dc:BibliographicResource","dc:abstract":"MEF2C haploinsufficiency syndrome is an emerging neurodevelopmental disorder associated with intellectual disability, autistic features, epilepsy, and abnormal movements. We report 16 new patients with MEF2C haploinsufficiency, including the oldest reported patient with MEF2C deletion at 5q14.3. We detail the neurobehavioral phenotype, epilepsy, and abnormal movements, and compare our subjects with those previously reported in the literature. We also investigate Mef2c expression in the developing mouse forebrain. A spectrum of neurofunctional deficits emerges, with hyperkinesis a consistent finding. Epilepsy varied from absent to severe, and included intractable myoclonic seizures and infantile spasms. Subjects with partial MEF2C deletion were statistically less likely to have epilepsy. Finally, we confirm that Mef2c is present both in dorsal primary neuroblasts and ventral gamma-aminobutyric acid(GABA)ergic interneurons in the forebrain of the developing mouse. Given interactions with several key neurodevelopmental genes such as ARX, FMR1, MECP2, and TBR1, it appears that MEF2C plays a role in several developmental stages of both dorsal and ventral neuronal cell types.","dc:creator":"Paciorkowski AR","dc:date":"2013","dc:title":"MEF2C Haploinsufficiency features consistent hyperkinesis, variable epilepsy, and has a role in dorsal and ventral neuronal developmental pathways."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23389741","rdfs:label":"LR11-310"}],"specifiedBy":"GeneValidityProbandADNullCriteria","strengthScore":0.1,"dc:description":"No variant evidence to support the pathogenicity of the variation, or effect on MEF2C function. Furthermore, there is no information on previous testing nor genotyping methods used, therefore I have reduced the score."}],"specifiedBy":"GeneValidityOverallAutosomalDominantNullVariantEvidenceCriteria","strengthScore":0.1},{"id":"cggv:34354e8f-4343-4fba-82ba-e49579e504bb_ad_dn_el","type":"EvidenceLine","evidence":[{"id":"cggv:15ab0feb-d4db-4885-89af-27867672f0c3_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:ad9c3450-c4ae-4a64-8c25-a5eae7eb1134","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"detectionMethod":"Singular or a combination of the following assays; molecular karyotyping using Genome-wide Human SNP array 6.0. MPLA for MEF2C exons, and PCR amplification of all coding exons of MEF2C and Sanger sequencing.","phenotypeFreeText":"Seizures began between 3-6 months","phenotypes":["obo:HP_0010864","obo:HP_0001250","obo:HP_0001388","obo:HP_0001290","obo:HP_0000337","obo:HP_0009748","obo:HP_0000486","obo:HP_0010804","obo:HP_0002360","obo:HP_0000582","obo:HP_0010832"],"previousTesting":true,"previousTestingDescription":"Conventional Karyotyping by GTG banding, subtelomeric FISH and/or MPLA were all normal. Molecular testing for TCF4, MECP2, CDKL5, UBE3A, and DMK came back normal. Also, 317K SNP array (Illumina) returned normal results.","sex":"Female","variant":{"id":"cggv:15ab0feb-d4db-4885-89af-27867672f0c3_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:928c6a36-5d3f-4e74-a915-4eca21c3b357","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.88804626_88804636del","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913184778"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/20513142","type":"dc:BibliographicResource","dc:abstract":"The etiology of mental retardation remains elusive in the majority of cases. Microdeletions within chromosomal bands 5q14.3q15 were recently identified as a recurrent cause of severe mental retardation, epilepsy, muscular hypotonia, and variable minor anomalies. By molecular karyotyping we identified two novel 2.4- and 1.5-Mb microdeletions of this region in patients with a similar phenotype. Both deletions contained the MEF2C gene, which is located proximally to the previously defined smallest region of overlap. Nevertheless, due to its known role in neurogenesis, we considered MEF2C as a phenocritical candidate gene for the 5q14.3q15 microdeletion phenotype. We therefore performed mutational analysis in 362 patients with severe mental retardation and found two truncating and two missense de novo mutations in MEF2C, establishing defects in this transcription factor as a novel relatively frequent autosomal dominant cause of severe mental retardation accounting for as much as 1.1% of patients. In these patients we found diminished MECP2 and CDKL5 expression in vivo, and transcriptional reporter assays indicated that MEF2C mutations diminish synergistic transactivation of E-box promoters including that of MECP2 and CDKL5. We therefore conclude that the phenotypic overlap of patients with MEF2C mutations and atypical Rett syndrome is due to the involvement of a common pathway.","dc:creator":"Zweier M","dc:date":"2010","dc:title":"Mutations in MEF2C from the 5q14.3q15 microdeletion syndrome region are a frequent cause of severe mental retardation and diminish MECP2 and CDKL5 expression."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/20513142","rdfs:label":"Zweier Case 7"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1,"dc:description":"Real time RT-PCR of MEF2C transcript(s) from patients blood show reduced expression levels of MEF2C transcript(s) (Figure 4). Of note, the authors state the variation in MEF2C occurred de novo, however there is no mention anywhere in the paper for this group that the parents were tested and found to be negative, therefore I have reduced the score."},{"id":"cggv:e01e7b16-716a-452d-bf97-cfd5b1367d53_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:f08a9c0b-23f1-42aa-8c1a-8661be302a4f","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":5,"detectionMethod":"NGS targeted sequencing panel of 512 genes associated with intellectual disability and or seizures, with particular focus on genes associated with Rett syndrome-like phenotypes.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Patient note to first lift/ raise head at 8 months, and sit alone at 1 year, with an inability to walk independently at 5 years and 9 months old. Hand stereotypies and grinding teeth (bruxism) noted to begin at 1 year old, followed by regression of hand skills. Seizures first noted at 20 months old, treated with valproate, oxcarbazepine, and topiramate showed improvement and control of seizures by 5.5 years old. EEG showed spike slow eaves in right medial and posterior temporal with generalization. MRI at 1 year showed enlarged frontal subarachnoid space.","phenotypes":["obo:HP_0011344","obo:HP_0000817","obo:HP_0001344","obo:HP_0003763","obo:HP_0002353","obo:HP_0002376","obo:HP_0012171","obo:HP_0001290","obo:HP_0001250","obo:HP_0007015","obo:HP_0010832","obo:HP_0000733"],"previousTesting":true,"previousTestingDescription":"MECP2, CDKL5, and FOXG1 mutational analysis was normal.","sex":"Female","variant":{"id":"cggv:e01e7b16-716a-452d-bf97-cfd5b1367d53_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:5a325ba2-4431-46fa-bc41-0505c9aa5a79","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.88823741G>C","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA360425261"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/30376817","type":"dc:BibliographicResource","dc:abstract":"MEF2C (Myocyte-specific enhancer factor 2C) has been associated with neurodevelopmental disorders. This study aimed at delineating the clinical profiles of MEF2C gene mutations.","dc:creator":"Wang J","dc:date":"2018","dc:title":"Novel MEF2C point mutations in Chinese patients with Rett (-like) syndrome or non-syndromic intellectual disability: insights into genotype-phenotype correlation."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30376817","rdfs:label":"Wang 2018 Patient 1"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5,"dc:description":"No variant evidence provided to support the pathogenicity of this missense mutation, however it did arise de novo. Due to lack of variant evidence I will downgrade the score as non-LOF."},{"id":"cggv:9a801a5b-7ebd-49ad-ae92-93d3510f1ef1_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:7e6f282f-6b7b-44af-a53b-054c2c58a258","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"detectionMethod":"Singular or a combination of the following assays; molecular karyotyping using Genome-wide Human SNP array 6.0. MPLA for MEF2C exons, and PCR amplification of all coding exons of MEF2C and Sanger sequencing.","phenotypeFreeText":"Seizures began at 10 months old. MRI showed generalized lack of white matter density and delayed myelin maturation.","phenotypes":["obo:HP_0002263","obo:HP_0010864","obo:HP_0000687","obo:HP_0000582","obo:HP_0002500","obo:HP_0000486","obo:HP_0000337","obo:HP_0001290","obo:HP_0009748","obo:HP_0011400","obo:HP_0001250","obo:HP_0003108","obo:HP_0000400"],"previousTesting":true,"previousTestingDescription":"Conventional Karyotyping by GTG banding, subtelomeric FISH and/or MPLA were all normal. Molecular testing for UBE3A, MECP2, CDKL5 and TCF4 testing was normal.","sex":"Female","variant":{"id":"cggv:9a801a5b-7ebd-49ad-ae92-93d3510f1ef1_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:901ce361-2653-4e9c-8cb2-9ca0a8cac667","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001131005.2(MEF2C):c.113T>A (p.Leu38Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/40214"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/20513142"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/20513142","rdfs:label":"Zweier P5"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":0.5,"dc:description":"Luciferase assays using a MADS consensus binding site and 4 E-boxes (transcription factor binding sites) showed significantly reduced transcriptional activity for the MEF2C-L38Q variant compared to wildtype MEF2C-MADS domain and controls (Figure 6A); reduction was also observed when using the MECP2 and CDKL5 promoter regions (Figure 6B and C). Of note, the authors state the variation in MEF2C occurred de novo, however there is no mention anywhere in the paper for this group that the parents were tested and found to be negative, therefore I have scored as a non loss of function (non-LOF) variant."},{"id":"cggv:b1506105-e93f-422c-9b6b-8eccfe50577a_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:3c8f985f-eab2-4bef-aa2c-b2cebd2d1dbe","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":5,"detectionMethod":"The 10 coding exons of MEF2C gene were amplified by PCR and sequenced.","firstTestingMethod":"PCR","phenotypeFreeText":"Developmental regression first noted at 5 months old. Behavioral changes noted include decreased eye contact, lack of emotional reciprocity, lack of interest in surroundings and stereotypic hand and mouth movements. General tonic clonic seizures noted, and valproate treatment was started at 9 months old.","phenotypes":["obo:HP_0010864","obo:HP_0001344","obo:HP_0002136","obo:HP_0001270","obo:HP_0000733","obo:HP_0011968","obo:HP_0100851","obo:HP_0000817","obo:HP_0030891","obo:HP_0002376","obo:HP_0000490","obo:HP_0006956","obo:HP_0002069"],"previousTesting":true,"previousTestingDescription":"Metabolic screening including lactic acid, pyruvic acid, ammoniac, plasmatic amino acids, urine organic acid analysis, purine metabolism, blood and urinary creatine and guanido-acetic acid were normal. High resolution chromosome analysis was normal and did not reveal any abnormalities. Genetic screens for MECP2 and CDKL5 mutations showed no variations in either gene. Array CGH was also performed and found normal.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:b1506105-e93f-422c-9b6b-8eccfe50577a_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:17f0e1da-964a-4bd2-a0b3-ce66cd929a69","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001131005.2(MEF2C):c.677C>G (p.Ser226Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA120008"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"No","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/19592390","type":"dc:BibliographicResource","dc:abstract":"Over the last few years, array-comparative genomic hybridisation (CGH) has considerably improved our ability to detect cryptic unbalanced rearrangements in patients with syndromic mental retardation.","dc:creator":"Le Meur N","dc:date":"2010","dc:title":"MEF2C haploinsufficiency caused by either microdeletion of the 5q14.3 region or mutation is responsible for severe mental retardation with stereotypic movements, epilepsy and/or cerebral malformations."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/19592390","rdfs:label":"Le Meur 2010 Case 7"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2,"dc:description":"De novo mutation, parents asserted as tested."},{"id":"cggv:f07321f3-2f6f-4a24-bf37-794a5a7ffb44_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:efdd745c-97f6-43cd-940a-0572b0c42497","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"detectionMethod":"A diagnostic panel for epileptic encephalopathies detected two mutations, MEF2C c.9A>T;p.R3S in exon 2 and SCN1A, c.5782C>G;.R1928G (heterozygous), inherited from father and gnomAD MAF is 0.004042 in Latino with 3 homozygotes, so benign.","phenotypeFreeText":"Born at 36 weeks gestation, birth parameters within normal range, although head circumference was -0.28 SD. first evaluated at 11 months for psychomotor delay and absence of axial control. Was noted to have hand stereotypies, including bringing hands to mouth frequently, biting and hurting his fingers (at 20 months). Seizures began at 26 months (not due to fever), including psychomotor arrest and sudden drops of the head associated with myoclonic seizures. EEG indicated abnormal, slow background pattern (theta waves with poor reactivity), focal right frontal hemispheric discharges with frequent generalization. Seizures noted as being difficult to treat, patient was placed on a combination of different drugs including valproate, lamotrigine, levetiracetam, clobazam, clonazepam, topiramate vigabatrin, carbamazepine and zonisamide until successful cessation was achevied. Final antiepileptic treatment is lamotrigine (5mg/kg/day and clobazam 0.33 mg/kg/day). MRI showed periventricular white matter signals, and enlarged CSF spaces (cortical sulcus) in the absence of parenchymal abnormalities. At 10 years old he cannot walk.","phenotypes":["obo:HP_0001344","obo:HP_0000733","obo:HP_0000400","obo:HP_0000337","obo:HP_0002487","obo:HP_0000817","obo:HP_0001250","obo:HP_0000687","obo:HP_0001263","obo:HP_0010819","obo:HP_0001290","obo:HP_0005280","obo:HP_0020045","obo:HP_0002518","obo:HP_0002123","obo:HP_0002263"],"previousTesting":true,"previousTestingDescription":"Biochemical metabolic screening including lactic acid, pyruvate acid, ammonia, plasmatic and urinary amino acids, acylcarnitine profile, urine organic acids, blood and urinary creatine, CSF analysis and karyotyping returned normal results. FMR molecular analysis excluded the most \"frequent mutation\" showing a normal allele.","sex":"Male","variant":{"id":"cggv:f07321f3-2f6f-4a24-bf37-794a5a7ffb44_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:a71b5572-be33-40f5-878e-4961a8542871","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001131005.2(MEF2C):c.9A>T (p.Arg3Ser)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/218315"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27255693","type":"dc:BibliographicResource","dc:abstract":"MEF2C haploinsufficiency syndrome is characterized by severe intellectual disability, epilepsy, stereotypic movements, minor dysmorphisms and brain abnormalities. We report the case of a patient with a new MEF2C mutation, comparing his clinical and imaging features to those previously reported in the literature.","dc:creator":"Rocha H","dc:date":"2016","dc:title":"MEF2C haploinsufficiency syndrome: Report of a new MEF2C mutation and review."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/27255693","rdfs:label":"Rocha 2016 Patient"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5,"dc:description":"No evidence to suggest the pathogenicity of this missense mutation, therefore I will reduce the points for point mutation as this exon has not been reported previously."},{"id":"cggv:43c6ae86-1d1f-4150-93b2-f48f1a352ab4_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:d401bc95-413e-4b35-967e-10503d6f0de3","type":"Proband","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":23,"detectionMethod":"NGS targeted sequencing panel of 512 genes associated with intellectual disability and or seizures, with particular focus on genes associated with Rett syndrome-like phenotypes.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Febrile convulsions were noted at 9 months, but no seizures at 23 months. She could sit alone at 1 year old and walk at 23 months. MRI showed hypomyelination at 1 year and 10 months old.","phenotypes":["obo:HP_0003763","obo:HP_0000733","obo:HP_0007015","obo:HP_0008872","obo:HP_0002373","obo:HP_0001263","obo:HP_0000817","obo:HP_0002360","obo:HP_0003429","obo:HP_0001270","obo:HP_0005957","obo:HP_0002205","obo:HP_0001290"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:43c6ae86-1d1f-4150-93b2-f48f1a352ab4_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:02d71f07-81a0-4bb8-b297-74da6a549b93","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.88761253C>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA360424570"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30376817"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30376817","rdfs:label":"Wang 2018 Patient 3"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5,"dc:description":"Authors indicate that the parental DNA was unable to be tested to confirm de novo status, therefore score as a LOF variant."},{"id":"cggv:9f1cb0e6-67a3-472e-a019-004abd61728d_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:1ac67fd8-0614-412a-b434-f0d1a27ec471","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"detectionMethod":"Next generation sequencing using a infantile epilepsy gene panel. Variation confirmed by PCR of MEF2C exon 3 and Sanger sequencing of the product.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Growth parameters at birth include birth weight of 3.20kg, height p25, weight p25 and head circumference p50. Sat independently at 12 months old, has not achieved independent walking. Seizures began at 1 year old (febrile and afebrile), treated with valproate and phenobarbital. Shown to rock in her chair. Noted as Happy disposition and likes human contact and interaction. EEG shows bilateral temporal slow waves and parietal spike waves. Noted as having prominent philtral pillars. Noted as having pale blue eyes.","phenotypes":["obo:HP_0002360","obo:HP_0002719","obo:HP_0010804","obo:HP_0011327","obo:HP_0001290","obo:HP_0002194","obo:HP_0012172","obo:HP_0005280","obo:HP_0002019","obo:HP_0000817","obo:HP_0000337","obo:HP_0040168","obo:HP_0100024","obo:HP_0012171","obo:HP_0025573","obo:HP_0002714","obo:HP_0002373","obo:HP_0001263","obo:HP_0002000","obo:HP_0000175","obo:HP_0000733","obo:HP_0031936","obo:HP_0002020","obo:HP_0001382","obo:HP_0001344","obo:HP_0003763"],"previousTesting":false,"previousTestingDescription":"","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:9f1cb0e6-67a3-472e-a019-004abd61728d_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:7f0b6b15-f415-4244-b217-dad38442e564","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.88804636C>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA360424843"}},"dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/28794905","type":"dc:BibliographicResource","dc:abstract":"Mutations in the MEF2C ( myocyte enhancer factor 2 ) gene have been established as a cause for an intellectual disability syndrome presenting with seizures, absence of speech, stereotypic movements, hypotonia, and limited ambulation. Phenotypic overlap with Rett's and Angelman's syndromes has been noted. Following the first reports of 5q14.3q15 microdeletions encompassing the MEF2C gene, further cases with point mutations and partial gene deletions of the MEF2C gene have been described. We present the clinical phenotype of our cohort of six patients with MEF2C mutations and compare our findings with previously reported patients as well as with a growing number of genetic conditions presenting with a severe neurodevelopmental, Rett-like, phenotype. We aim to add to the current knowledge of the natural history of the \"MEF2C haploinsufficiency syndrome\" as well as of the differential diagnosis, clinical management, and genetic counseling in this diagnostically challenging group of patients.","dc:creator":"VreÄar I","dc:date":"2017","dc:title":"Further Clinical Delineation of the MEF2C Haploinsufficiency Syndrome: Report on New Cases and Literature Review of Severe Neurodevelopmental Disorders Presenting with Seizures, Absent Speech, and Involuntary Movements."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/28794905","rdfs:label":"Vrecar 2017 Patient 5"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5,"dc:description":"The variation is a nonsense mutation that is located in the MEF2C DNA binding domain, and the authors note is predicted to be pathogenic according to MutationTaster. The Authors claim de novo status, however they did not specifically state that the parents had been genetically tested and found negative, therefore I will score as a loss of function (LOF) variant."},{"id":"cggv:99c53680-8c22-43f4-b62a-1c544b0c6007_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:bbae1615-18d2-49e9-90ca-7eb031d8451e","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"detectionMethod":"All exons and exon-intron boundaries of MEF2C isoforms 1 and 2 ( NM_002397.4 and NM_001131005.2) were amplified fromperipheral blood leukocytes by PCR. The PCR products were sequenced by the Sanger method.","firstTestingMethod":"PCR","phenotypeFreeText":"Began walking at 4 years of age. Seizures began at 18 months of age, with a single myoclonic febrile seizure, and they are now controlled by valproate. EEG indicated low, generalized spike waves, with massive myoclonies presenting followed by pikes of bifrontal slow waves. At 7 years and 4 months of age, all growth parameters, including head circumference, ody weight, and body height were at least 2 SD or more below average. Brain MRI was reported as normal. The stereotypic movements included hand washing, clapping, and predominantly hand-mouth movements.","phenotypes":["obo:HP_0004322","obo:HP_0010845","obo:HP_0001250","obo:HP_0000486","obo:HP_0001270","obo:HP_0011344","obo:HP_0040082","obo:HP_0008872","obo:HP_0001344","obo:HP_0004325","obo:HP_0000733","obo:HP_0000194","obo:HP_0001298","obo:HP_0005484","obo:HP_0000463","obo:HP_0000232","obo:HP_0011229","obo:HP_0001290","obo:HP_0002136"],"previousTesting":true,"previousTestingDescription":"No chromosomal abnormalitites were observed. Methylation studies for Angelman syndrome were normal. Mutational analysis of MECP2, CDKL5, and FOXG1 were normal. array-CGH 944K analysis) was normal.","secondTestingMethod":"Sanger sequencing","sex":"Female","variant":{"id":"cggv:99c53680-8c22-43f4-b62a-1c544b0c6007_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:8c0d42ee-2959-4d91-be44-153dc6e82ba9","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002397.4(MEF2C):c.458delA (p.Asn153Thrfs)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/40217"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"paternityMaternityConfirmed":"Yes","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/23001426","type":"dc:BibliographicResource","dc:abstract":"Up to now, only five-point mutations in the MEF2C gene have been described in patients with severe mental retardation with absent speech, limited walking abilities, epilepsy, and lack of gross malformations. In brain, MEF2C is essential for early neurogenesis, neuronal migration, and differentiation. Here, we present a new patient with severe mental retardation, epilepsy, and hand stereotypies associated with a novel MEF2C frameshift mutation c.457delA. The purpose of this work was to clarify criteria for the selection of patients with severe intellectual disability to screen for deficiency in the MEF2C gene. By combining the clinical data of all patients with MEF2C point mutations published so far with the phenotype of our patient, a targeted search for MEF2C mutations could be applied to patients with a severe intellectual deficiency associated with absence of language and hypotonia, strabismus, and epilepsy (started after 6 months, often well controlled by valproate).","dc:creator":"Bienvenu T","dc:date":"2013","dc:title":"Refining the phenotype associated with MEF2C point mutations."}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/23001426","rdfs:label":"Bienvenue Case 1"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5,"dc:description":"No variant evidence was provided to support the pathogenicity of the frameshift, or to indicate that the MEF2C protein undergoes NMD due to the variation,  therefore I have reduced the score to 1.5 to be conservative."},{"id":"cggv:909162bc-af24-4d83-82be-0067b5b055d1_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:2eb88b33-ddcc-4aaa-b539-107c36e86523","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":7,"detectionMethod":"NGS targeted sequencing panel of 512 genes associated with intellectual disability and or seizures, with particular focus on genes associated with Rett syndrome-like phenotypes.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Noted as holding head up at 1 year, sitting alone at 1 year and 2 months, and walking at 1.5 years old. Febrile seizures began at 1 year old which progressed to afebrile seizures at 2 years old. Seizure occurence was 1-2 times per month, lasting for a few minutes to half an hour. Valproate was administered at 2.5 years with 4 years eizure free. EEG at 2.5 years showed multiple spike and slow waves in the right occipital region, with slow rhythm on the background.","phenotypes":["obo:HP_0000817","obo:HP_0001263","obo:HP_0001344"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:909162bc-af24-4d83-82be-0067b5b055d1_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:c099e75f-b0a5-4e76-a158-10c07e8664de","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.88752044C>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA360424067"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30376817"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30376817","rdfs:label":"Wang 2018 Patient 4,"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5,"dc:description":"No variant evidence to support the pathogenicity of this splice site mutation, will reduce the points from the default de novo status in the absence of variant evidence."},{"id":"cggv:062ecb93-a77c-4ea2-b91a-dfc52d9e17a0_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:ddcafa7e-9338-4f2d-ab28-242ebb698a0a","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":10,"detectionMethod":"Singular or a combination of the following assays; molecular karyotyping using Genome-wide Human SNP array 6.0. MPLA for MEF2C exons, and PCR amplification of all coding exons of MEF2C and Sanger sequencing.","phenotypeFreeText":"Seizure began at 6 months. the hypomyelination was observed bilaterally in the insular cortices. The hyperventilation was episodic. Began walking at 8 years old, requires support. Nails noted to grow quickly.","phenotypes":["obo:HP_0003429","obo:HP_0010864","obo:HP_0001270","obo:HP_0001290","obo:HP_0002883","obo:HP_0001250","obo:HP_0009748","obo:HP_0000494","obo:HP_0000486","obo:HP_0000400","obo:HP_0000678","obo:HP_0100874","obo:HP_0000337"],"previousTesting":true,"previousTestingDescription":"Conventional Karyotyping by GTG banding, subtelomeric FISH and/or MPLA were all normal. Molecular testing for UBE3A, MECP2, CDKL5 and TCF4 testing was normal.","sex":"Female","variant":{"id":"cggv:062ecb93-a77c-4ea2-b91a-dfc52d9e17a0_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:15b4579a-a19c-4c2e-b99d-0669b4d31fac","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_001131005.2(MEF2C):c.80G>C (p.Gly27Ala)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA130789"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/20513142"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/20513142","rdfs:label":"Zweier Case 8"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":0.5,"dc:description":"Luciferase assays using a MADS consensus binding site and 4 E-boxes (transcription factor binding sites) showed significantly reduced transcriptional activity for the MEF2C-G27A variant compared to wildtype MEF2C-MADS domain and controls (Figure 6A); reduction was also observed when using the MECP2 and CDKL5 promoter regions (Figure 6B and C). Of note, the authors state the variation in MEF2C occurred de novo, however there is no mention anywhere in the paper for this group that the parents were tested and found to be negative, therefore I have scored as a non loss of function (non-LOF) variant."},{"id":"cggv:699b0051-a1ca-41cc-aef6-ac348d4c2a66_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:6ada1f4e-e0a4-4f50-b0d2-5830e0e349e3","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":6,"detectionMethod":"NGS targeted sequencing panel of 512 genes associated with intellectual disability and or seizures, with particular focus on genes associated with Rett syndrome-like phenotypes.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"Developmental milestones include rising head at 7 months, sitting alone at 1 year, and walking at 2 years old. Seizures first noted at 8 months with febrile, with attacks noted 2-3 times per year. Treatment with valproate and levetiracetam showed seizure free for 4 months. MRI at 4 years old showed signal around bilateral ventricle on T1 and T2, and a septum pellucidum cyst.","phenotypes":["obo:HP_0000817","obo:HP_0000750","obo:HP_0000733","obo:HP_0007375","obo:HP_0010864"],"previousTesting":false,"previousTestingDescription":"","sex":"Male","variant":{"id":"cggv:699b0051-a1ca-41cc-aef6-ac348d4c2a66_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:6cada291-0555-43a9-ba25-7ad3f9bed743","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.88731773G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA315931"}},"alleleOrigin":{"id":"obo:GENO_0000880"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30376817"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30376817","rdfs:label":"Wang 2018 Patient 5"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":2},{"id":"cggv:c6598c1a-168f-4e2b-bf51-72b6359c6f6a_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:a5b40cf4-8c79-4c11-a629-9f0243700ad8","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":14,"detectionMethod":"Singular or a combination of the following assays; molecular karyotyping using Genome-wide Human SNP array 6.0. MPLA for MEF2C exons, and PCR amplification of all coding exons of MEF2C and Sanger sequencing.","phenotypeFreeText":"Seizures began at 10 months old and noted as being complex partial (which is an equivalent term to HPO term Focal impaired awareness seizure, HP:0002384). Walking began at 2 years and 8 months. The macrotia is noted as mild.","phenotypes":["obo:HP_0002119","obo:HP_0002263","obo:HP_0001270","obo:HP_0000729","obo:HP_0002384","obo:HP_0010864","obo:HP_0000400","obo:HP_0000540","obo:HP_0000582","obo:HP_0001276","obo:HP_0000337","obo:HP_0009748","obo:HP_0000687","obo:HP_0011968"],"previousTesting":true,"previousTestingDescription":"Conventional Karyotyping by GTG banding, subtelomeric FISH and/or MPLA were all normal. Molecular testing for UBE3A, MECP2 and CDKL5 testing was normal.","sex":"Male","variant":{"id":"cggv:c6598c1a-168f-4e2b-bf51-72b6359c6f6a_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:1ed2a595-85ad-4275-82a3-f9bcfae733d5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NC_000005.10:g.88804757dup","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA913184777"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/20513142"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/20513142","rdfs:label":"Zweier Case 6"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5,"dc:description":"Real time RT-PCR of MEF2C transcript(s) from patients blood show reduced expression levels of MEF2C transcript(s), indicating partial loss of function (Figure 4). Luciferase assays using a MADS consensus binding site and 4 E-boxes (transcription factor binding sites) showed significantly reduced transcriptional activity for the MEF2C-E34X variant compared to wildtype MEF2C-MADS domain and controls (Figure 6A); reduction was also observed when using the MECP2 and CDKL5 promoter regions (Figure 6B and C). Of note, the authors state the variation in MEF2C occurred de novo, however there is no mention anywhere in the paper for this group that the parents were tested and found to be negative, therefore I have reduced the score."},{"id":"cggv:9ccc9edf-773c-435d-af7d-12ee1e9ceffd_proband_score_evidence_line","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:833cfc62-94b9-484a-8e78-a7ce02059c7e","type":"Proband","ageType":"AgeAtReport","ageUnit":"Years","ageValue":2,"detectionMethod":"NGS targeted sequencing panel of 512 genes associated with intellectual disability and or seizures, with particular focus on genes associated with Rett syndrome-like phenotypes.","firstTestingMethod":"Next generation sequencing panels","phenotypeFreeText":"control of head at 5 months and sitting alone at 8 months. Was not able to walk or talk at 2.5 years. No seizures but EEG shows epileptiform discharge at 2 years. MRI showed high T1 and T2 signal in posterior horn of bilateral ventricle.","phenotypes":["obo:HP_0001290","obo:HP_0000817","obo:HP_0003763","obo:HP_0001263","obo:HP_0007015","obo:HP_0001344","obo:HP_0010864","obo:HP_0001270","obo:HP_0000733"],"previousTesting":false,"previousTestingDescription":"","sex":"Female","variant":{"id":"cggv:9ccc9edf-773c-435d-af7d-12ee1e9ceffd_variant_evidence_item","type":"MolecularSequenceObservation","allele":{"id":"cggv:efd14cb1-71c6-4333-9355-97eb1309de68","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_002397.4(MEF2C):c.565C>T (p.Arg189Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"https://www.ncbi.nlm.nih.gov/clinvar/variation/158886"}},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30376817"},"dc:source":"https://pubmed.ncbi.nlm.nih.gov/30376817","rdfs:label":"Wang 2018 Patient 2"}],"specifiedBy":"GeneValidityProbandADDeNovoCriteria","strengthScore":1.5,"dc:description":"Authors indicate that the parental DNA was unable to be tested to confirm de novo status, therefore score as a LOF variant."}],"specifiedBy":"GeneValidityOverallAutosomalDominantDeNovoVariantEvidenceCriteria","strengthScore":12}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"cggv:34354e8f-4343-4fba-82ba-e49579e504bb_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:34354e8f-4343-4fba-82ba-e49579e504bb_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:718c6cbd-d11d-4e19-ba28-f00bd0f6c6db","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:c315da46-9f1a-455b-94a8-a94419f534fb","type":"Finding","demonstrates":{"id":"cg:GeneExpressionA"},"dc:description":"Quantitative RT-PCR for MEF2C transcripts corresponding to isoforms 1 and 2 was performed on human fetal and adult tissues, including brain, muscle, heart, kidney, lung, and liver. The highest levels of isoform 1 expression were observed in fetal brain. For isoform 2 the highest expression levels were observed in fetal and adult muscle, with lower levels observed in heart, brain, kidney and lung (Figure 3).","dc:source":"https://pubmed.ncbi.nlm.nih.gov/20513142","rdfs:label":"MEF2C is highly expressed in fetal human brain"}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":0.5},{"id":"cggv:9ba4b7fc-fe81-43f7-8717-1726bd72d394","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"cggv:199f20a0-f7a4-4255-8fcd-bbba096778f4","type":"Finding","demonstrates":{"id":"cg:BiochemicalFunctionA"},"dc:description":"TCF4 is a bHLH transcription factor that is shown to regulate gene expression in neurons consistent with neuronal function. Similarly, EF2C is a transcription factor that regulates neuronal function and differentiation. Both of these transcription factors have been implicated in the regulation of genes associated with autism and ID including NRXN1.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/7679508","type":"dc:BibliographicResource","dc:abstract":"We have cloned cDNA encoding a human transcription factor that belongs to the MEF2 (myocyte-specific enhancer-binding factor 2) subfamily of the MADS (MCM1-agamous-deficiens-serum response factor) gene family. This factor, which we have named MEF2C, binds specifically to the MEF2 element and activates transcription via this element. Specific isoforms of this factor are found exclusively in brain and are robustly expressed by neurons in cerebral cortex. In situ hybridization indicates that the factor is expressed preferentially in certain neuronal layers of cortex and that expression declines during postnatal development. The unusual pattern of expression in brain suggests that this transcription factor may be important in the development of cortical architecture.","dc:creator":"Leifer D","dc:date":"1993","dc:title":"MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex."},"rdfs:label":"MEF2C is a transcription factor"}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1},{"id":"cggv:34354e8f-4343-4fba-82ba-e49579e504bb_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"cggv:f8d81fda-73a2-4ad8-99a3-812844ef5834","type":"EvidenceLine","calculatedScore":2,"direction":"Supports","evidence":[{"id":"cggv:a0ac045c-050c-4dc0-bc40-2196916d519f","type":"Finding","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"},"dc:description":"The homozygous MEF2C floxed, Emx1-Cre mice (Mef2c cKO) were tested for a number of behavioral paradigms associated with learning and memory, and social interaction. Ultrasonic vocalization (USVs) were recorded in Mef2c cKO mice versus control littermates. The Mef2c cKO adult male mice prodiced 70% fewer USV calls in the presence of a sexually-receptive female than control littermates (Figure 5B). furthermore, the type of USC being produced by the Mef2C cKO mice varied significantly compared to wildtype littermates. When infantile mice (postnatal day 4-10) were recorded for USV production, the Mef2c cKO mice produced fewwer USVs than control littermates (figure 5D), supporting reduction in communication which is consistent with the absence of speech and/or language impairment observed in humans with MEF2C variants.\n\nIn the three chamber assay to test for sociability, the Mef2c cKO equally preferred the chamber housing another mouse than the empty chamber similar to control mice, however the Mef2c cKO did spend significantly less time interacting with the mouse in the chamber compared to control mice (figure 5E). This deficits was shown to be independent of any deficit in olfaction (Figure 5F). Nest building was also tested, and the Mef2c cKO mice showed significantly less structured nest building than control littermates (figure 5G). The Mef2C cKO also showed deficits in the sucrose preference test, indicating difference in reward-related behavior.\n\nMef2c cKO mice showed an increase in repetitive jumping behavior, with a 3 fold increase in both novel and home cage setting compared to control littermates (Figure 6A). This was also true of repetitive fine motor movements (Figure 6B). Hyperactivity was noted in the novel open cage paradigm (Figure 6D).\n\nMef2C cKO mice also showed significant deficits in the fear conditioning assays (figure 7C-E), in which robust freezing behaviors were not observed following tone-shock pairing, unlike that observed in the control littermates.\n\nLastly, RNA-seq performed on the somatosensory cortex of Mef2c cKO mice showed significantly reduced expression of gene associated with autism including Ntng1, Nlgn1, Nrxn1, Nrxn3, Pcdh19, Shank2, Shank3, Pten, and Htr1b.","dc:source":{"id":"https://pubmed.ncbi.nlm.nih.gov/27779093","type":"dc:BibliographicResource","dc:abstract":"Numerous genetic variants associated with MEF2C are linked to autism, intellectual disability (ID) and schizophrenia (SCZ) - a heterogeneous collection of neurodevelopmental disorders with unclear pathophysiology. MEF2C is highly expressed in developing cortical excitatory neurons, but its role in their development remains unclear. We show here that conditional embryonic deletion of Mef2c in cortical and hippocampal excitatory neurons (Emx1-lineage) produces a dramatic reduction in cortical network activity in vivo, due in part to a dramatic increase in inhibitory and a decrease in excitatory synaptic transmission. In addition, we find that MEF2C regulates E/I synapse density predominantly as a cell-autonomous, transcriptional repressor. Analysis of differential gene expression in Mef2c mutant cortex identified a significant overlap with numerous synapse- and autism-linked genes, and the Mef2c mutant mice displayed numerous behaviors reminiscent of autism, ID and SCZ, suggesting that perturbing MEF2C function in neocortex can produce autistic- and ID-like behaviors in mice.","dc:creator":"Harrington AJ","dc:date":"2016","dc:title":"MEF2C regulates cortical inhibitory and excitatory synapses and behaviors relevant to neurodevelopmental disorders."},"rdfs:label":"MEF2C Neocortical and hippocampal KO mice"}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":3,"dc:description":"This mouse model follows the molecular mechanism described in the humans with MEF2C variation (loss of function) and outlines several behavioral deficits that are consistent with learning and memory and social deficits. Furthermore, RNA-seq performed on specific brain regions in the knockout mice show reduction in the expression of genes associated with Autism and intellectual disability, therefore I am increasing the score."}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":3}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":4}],"evidenceStrength":"Definitive","sequence":36,"specifiedBy":"GeneValidityCriteria6","strengthScore":16,"subject":{"id":"cggv:a31d47ed-7bfc-4f81-8755-746229bda350","type":"GeneValidityProposition","disease":"obo:MONDO_0100038","gene":"hgnc:6996","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","dc:description":"MEF2C was first reported in relation to autosomal dominant complex neurodevelopmental disorder in 2010 (Le Meur et al., 2010 PMID:19592390; Zweier et al., 2010 PMID:20513142). At least 14 unique variants (e.g. missense, nonsense, frameshift, small deletions, and large deletions) have been reported in humans. Evidence supporting this gene-disease relationship includes case-level data and experimental data. Variants in this gene have been reported in at least 14 cases, in 7 publications (PMIDs: 19592390, 20513142, 23001426, 23389741, 27255693, 28794905, 30376817). More evidence is available in the literature, but the maximum score for genetic evidence (12 points) has been reached. The mechanism for disease appears to be de novo, loss of function. MEF2C is associated with the following disease entities per OMIM: (1) Chromosome 5q14.3 deletion syndrome (MIM:613443); and (2) Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations (MIM:613443). Note that these two disease entities share the same MIM number indicating they may be the same disease. However, per the criteria outlined by the ClinGen Lumping and Splitting Working Group, we found that the Chromosome 5q14.3 deletion syndrome is a contiguous gene deletion syndrome involving multiple genes of interest beyond MEF2C, including the gene RASA1, exemplifying different molecular mechanisms. Furthermore, the Chromosome 5q14.3 deletion syndrome is associated with a skin phenotype that is not found in individuals with isolated variation in the MEF2C gene. Therefore, we have split into two disease entities; this curation represents the relationship between MEF2C and Complex Neurodevelopmental disorder (MONDO:0100038) (intellectual disability, stereotypic movements, epilepsy, and/or cerebral malformations phenotype) only, in accordance to assertions made in the literature (Paciorkowski et al., 2013 PMID:23389741). This gene-disease association is supported by biochemical function, expression studies, and animal models. In summary, MEF2C is DEFINITIVELY associated with autosomal dominant complex neurodevelopmental disorder. This has been repeatedly demonstrated in both the research and clinical diagnostic settings, and has been upheld over time. This classification was approved by the ClinGen Autism and Intellectual Disability Gene Curation Expert Panel on February 6, 2019 (SOP Version 6).\n","dc:isVersionOf":{"id":"cggv:34354e8f-4343-4fba-82ba-e49579e504bb"},"@context":{"@vocab":"http://dataexchange.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"http://dataexchange.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"http://dataexchange.clinicalgenome.org/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"}}}